Glycoprotein IIb/IIIa Antagonists in Acute Coronary Syndromes: Where Are We Now?

Seminars in Vascular Medicine

Volumn 3, Issue 4, 2003, Pages 385-390

  Maree, Andrew ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Glycoprotein IIb IIIa antagonist; Inflammation; Partial agonist; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LAMIFIBAN; LOW MOLECULAR WEIGHT HEPARIN; PARTIAL AGONIST; THROMBOCYTE RECEPTOR; TIROFIBAN;

ACUTE DISEASE; CLINICAL TRIAL; CORONARY ARTERY CONSTRICTION; DRUG RESPONSE; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RECEPTOR OCCUPANCY; REVIEW; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOSIS;

ACUTE DISEASE; CORONARY DISEASE; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SYNDROME;

EID: 1642575979     PISSN: 15289648     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-817687     Document Type: Review

References (23)

1. Angelillo-Scherrer A, de Frutos P, Aparicio C, et al. Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat Med 2001;7:215-221
2. Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS, Jordan RE. Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood 1996;88:907-914
3. Nurden A. Human platelet glycoproteins. In: Bloom A, Forbes CD, eds. Haemostasis and Thrombosis. 3rd ed. New York: Churchill Livingstone; 1994:115-165
4. Plow EF, D'Sousa SE, Ginsberg MH. Ligand binding to GPIIb-IIIa: a status report. Semin Thromb Hemost 1992;18: 324-332
5. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb) beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002;106:2111-2117
6. Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594
7. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT. Flow cytometry reveals activated GP IIb-IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrinolysis 1995; 6:395-410
8. Quinn M, Lincoff AM, Kereiakes D, et al. Long-term mortality benefit of abciximab in percutaneous intervention. Circulation 2001;104:II-387
9. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96:1445-1453
10. The ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000;356:2037-2044
11. Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344: 1888-1894
12. Batchelor WB, Tolleson TR, Huaung Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Circulation 2002;106:1470-1476
13. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Circulation 2002;106:1893-1900
14. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1905-1914
15. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-1497
16. O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med 2000;342:1316-1324
17. Chew DP, Bhatt DL. Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Curr Cardiol Rep 2001;3:63-71
18. Fitzgerald D. J., Roy L., Catella F., FitzGerald G. A. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315:983-989
19. Cox D, Smith R, Quinn M, Theroux P, Crean P, Fitzgerald DJ. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000;36:1514-1519
20. Blystone SD. Kinetic regulation of beta 3 integrin tyrosine phosphorylation. J Biol Chem 2002;277:46886-46890
21. May AE, Kalsch T, Massberg S, Herouy Y, Schmidt R, Gawaz M. Engagement of glycoprotein IIb/IIIa (alpha(IIb) beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation 2002;106:2111-2117
22. O'Donnell C, Larson MG, Feng D, et al. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001;103:3051-3056
23. Adderley SR, Fitzgerald DJ. Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J Biol Chem 2000;275:5760-5766